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Abstract
Background: Drug-related toxicity has been one of the main causes of antiretroviral treatment discontinuation.
However, its determinants are not fully understood. Aim of this study was to investigate predictors of first-line
antiretroviral therapy discontinuation due to adverse events and their evolution in recent years.
Methods: Patients starting first-line antiretroviral therapy were retrospectively selected. Primary end-point was the
time to discontinuation of therapy due to adverse events, estimating incidence, fitting Kaplan-Meier and
multivariable Cox regression models upon clinical/demographic/chemical baseline patients’ markers.
Results: 1,096 patients were included: 302 discontinuations for adverse events were observed over 1,861 person
years of follow-up between 1988 and 2010, corresponding to an incidence (95% CI) of 0.16 (0.14-0.18). By
Kaplan-Meier estimation, the probabilities (95% CI) of being free from an adverse event at 90 days, 180 days, one
year, two years, and five years were 0.88 (0.86-0.90), 0.85 (0.83-0.87), 0.79 (0.76-0.81), 0.70 (0.67-0.74), 0.55 (0.50-0.61),
respectively. The most represented adverse events were gastrointestinal symptoms (28.5%), hematological (13.2%)
or metabolic (lipid and glucose metabolism, lipodystrophy) (11.3%) toxicities and hypersensitivity reactions (9.3%).
Factors associated with an increased hazard of adverse events were: older age, CDC stage C, female gender, homo/
bisexual risk group (vs. heterosexual), HBsAg-positivity. Among drugs, zidovudine, stavudine, zalcitabine, didanosine,
full-dose ritonavir, indinavir but also efavirenz (actually recommended for first-line regimens) were associated to an
increased hazard of toxicity. Moreover, patients infected by HIV genotype F1 showed a trend for a higher risk of
adverse events.
Conclusions: After starting antiretroviral therapy, the probability of remaining free from adverse events seems to
decrease over time. Among drugs associated with increased toxicity, only one is currently recommended for
first-line regimens but with improved drug formulation. Older age, CDC stage, MSM risk factor and gender are also
associated with an increased hazard of toxicity and should be considered when designing a first-line regimen.
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Background
Combination antiretroviral therapy (cART) has markedly
changed the prognosis of HIV-infected patients, redu-
cing AIDS-related morbidity and mortality [1]. Rates of
virological failure during first line regimens are decrea-
sing both in clinical trials and in studies performed du-
ring routine clinical practice [2,3]. However, drug-related
adverse events and toxicities are increasingly recognized
[4-7] and represent one of the most common reasons
for treatment discontinuation or switch [2,3,8-11]. In re-
cent years, the introduction of newer antiretroviral
agents with improved efficacy and tolerability profiles
has allowed for a decline of treatment-limiting toxic
effects; however, drug-related adverse events still repre-
sent an issue of concern.
Treatment-limiting cART toxicity has been associated
with several factors such as demographical characteris-
tics, drug-drug interactions, co-morbidities and recently
genetic factors [12]. However, determinants of toxicity
are not fully understood. In particular, the role of newer
and apparently better tolerated antiretroviral drugs
needs to be fully investigated. Moreover, the influence of
baseline chemistry remains to be elucidated.
The aim of this study is to investigate predictors of
first-line antiretroviral therapy discontinuation due to
adverse events and their evolution in more recent years,
characterized by an increased use of regimens with bet-
ter tolerability profiles. In particular, the analysis is fo-
cused on the evaluation of baseline demographic and
clinical characteristics, prescribed drugs and chemical
parameters which could represent objective tools to
tailor regimens on patients’ characteristics.
Methods
HIV-infected patients followed up at the Infectious Dis-
eases Clinic of the Catholic University of the Sacred
Heart (CUSH) in Rome, Italy, starting a first-line anti-
HIV antiretroviral therapy, were screened retrospectively
via the electronic CUSH data base, which includes data
on more than 4,300 HIV-infected patients, with the first
available anti-HIV therapy record dated 1988. All
patients included in the data base had previously signed
an informed consent to be included in observational
studies. Access and data analyses of the CUSH data base
are regulated by an institutional internal ethics commit-
tee and conform to Italian and European privacy legisla-
tions. The latest available updated version (up to January
2011) of the CUSH data base was used.
The baseline time was the start date of the anti-HIV
antiretroviral therapy. The end-point of interest was
the discontinuation date of the first-line anti-HIV anti-
retroviral therapy. Discontinuation was defined as stop-
ping any antiretroviral drug for at least 2 weeks or
switching (changing one or more drugs) to another
regimen; the only exception was a substitution of lamivu-
dine with emtricitabine or vice-versa, because it could
simply reflect a shift to a fixed dose formulation of
tenofovir-emtricitabine, abacavir-lamivudine or zidovudine-
lamivudine. An adverse event was marked if the reason
of discontinuation or switch (or eventually a concomitant
death) was an event corresponding to toxicity or allergy;
otherwise data were censored at that time point or at
the latest available time point if the patient did not stop
that therapy, following a cause-specific approach. All dis-
continuation causes were ascertained by electronic and
clinical reports (see Table 1 for categories besides the ad-
verse event definition). In case of a decease event without
a prior therapy discontinuation date, data were censored
as well. First-line anti-HIV antiretroviral therapies with a
known stop date, but unknown reason of stop or decease,
were not included in the study population.
Covariates of interest, contemporary or the closest
previous to the baseline date, were: calendar year,
patient’s gender, age, nationality, risk group, first date of
HIV-positive antibody test, CDC stage, viral subtype,
anti-HIV antiretroviral therapy, HIV-RNA load, CD4+
T cell count, hepatitis C co-infection (HCVAb), hepatitis
B co-infection (HBsAg), anti-HCV interferon/ribavirin
treatment, anti-Mycobacterium Tuberculosis (TB) therapy,
anti-Pneumocystis jirovecii pneumonia (PCP) therapy,
other antibiotic treatments, other concomitant (prescrip-
tion or over-the-counter) drugs exposure, total bilirubin,
total cholesterol, hemoglobin, glucose, glutamate pyru-
vate transaminases (GPT), gamma-glutamyltransferase
(gammaGT), high-density lipoprotein (HDL), low-density
lipoprotein (LDL), triglycerides (TGL), and glomerular
filtration rate (GFR) estimated by modification of diet in
renal disease (MDRD) formula. Chemistry parameters
were classified as normal, high or low according to estab-
lished cut-offs [13,14] (see Table 2 for cut-off values).
The covariate list was consistent with other European
cohort studies [15,16]. Baseline chemistry variables were
registered in the database only for patients starting anti-
retroviral therapy after 1998; when not available, they
were encoded as unknown.
The antiretroviral therapy was encoded in different
ways: (i) as a combination therapy of 2 nucleoside re-
verse transcriptase inhibitors (NRTI) + 1 non-nucleoside
reverse transcriptase inhibitor (NNRTI), 2 NRTI + 1
protease inhibitor (PI), 2 NRTI + 1 PI boosted with
ritonavir (PI/r), and other combinations; (ii) as single
compounds, i.e. emtricitabine, lamivudine, abacavir, zi-
dovudine, stavudine, zaltacibine, didanosine, tenofovir,
nevirapine, efavirenz, atazanavir, fosamprenavir, indina-
vir, lopinavir, nelfinavir, ritonavir full or boosting dose,
and saquinavir; (iii) as a combination therapy of different
brand names, including those combinations with a
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frequency of at least 10; (iv) as TruvadaW + SustivaW,
AtriplaW, ReyatazW, KaletraW, any other NRTI+PI, any
other NRTI+PI/r, any other NRTI+NNRTI, and other
combinations. Other compounds including enfuvurtide,
maraviroc, raltegravir, darunavir, and etravirine, were not
included due to their low frequency.
Statistical methods included descriptive summaries,
calculation of incidence ratios and confidence intervals,
Kaplan-Meier estimation for the probability of surviving
an adverse event, multivariable proportional-hazard hy-
pothesis testing, and multivariable Cox model fitting in
order to identify factors associated to an increased/
reduced hazard of an adverse event happening. Effect of
covariate interactions and nested model comparison via
ANOVA were also carried out. All statistical analyses
were carried out using R software (www.r-project.org).
Results
The total number of HIV-positive patients recorded in
the CUSH data base (up to January 2011) was 4,388.
Those with at least one anti-HIV therapy registered were
2,455, and 1,218 for which it was the actual first-line. Of
these, 1,096 had a documented reason of discontinuation
or did not stop the therapy and met the inclusion cri-
teria, starting their first-line anti-HIV therapy between
year 1988 and 2010 (median 2003, interquartile range
1998–2006). Of these patients, 317 started the first-line
anti-HIV therapy prior to 1999 (154 before 1997), whilst
779 afterwards (Figure 1). Tables 3 and 2 list patients’
demographic/clinical characteristics and chemical mar-
kers at the baseline date, concomitant to the first-line
anti-HIV therapy start date. Also, Additional file 1 shows
the distribution of patients under different first-line ther-
apy regimens per calendar year, using both encoding (i)
and (iv).
The observed number of therapy discontinuations for
adverse events (toxicity/allergy) was 302, over 1,861 per-
son years of follow up, corresponding to an incidence
(95% confidence intervals, CI) of 0.16 (0.14-0.18) per
person years of follow up (PYFU). Table 1 summarizes
in detail the causes of anti-HIV first-line therapy discon-
tinuation. The most represented adverse events were
gastrointestinal symptoms (28.5%), hematological (13.2%)
or metabolic (lipid and glucose metabolism, lipodystrophy)
(11.3%) toxicities and hypersensitivity reactions (9.3%). By
a Kaplan-Meier estimation, the probabilities (95% CI) of
being free from an adverse event at 90 days, 180 days,
one year, two years, and five years were 0.88 (0.86-0.90),
0.85 (0.83-0.87), 0.79 (0.76-0.81), 0.70 (0.67-0.74), 0.55
(0.50-0.61), respectively. Figure 2 shows the Kaplan-
Meier curves overall and stratified for gender, risk group,
CDC stage at baseline. The test of proportional-hazard
Table 1 Causes of anti-HIV first-line therapy discontinuation in the study population (n=1,096)
Type Tot Strata n % Over strata % Over total
Adverse events
(toxicity/allergy)
302 (1 death) Gastrointestinal 86 28.5% 7.8%
Hypersensitivity 28 9.3% 2.6%
Central nervous system 18 6.0% 1.6%




Renal 13 4.3% 1.2%
Hematologic 40 13.2% 3.6%
Other 69 22.8% 6.3%
Other causes 618 Simplification 252 40.8% 23.0%
Patient’s choice 93 15.0% 8.5%
Failure 86 13.9% 7.8%
Regimen intensification 59 9.5% 5.4%
Genotype-guided switch 20 3.2% 1.8%
Low adherence 19 3.1% 1.7%
End of pregnancy 16 2.6% 1.5%
Structured interruption 13 2.1% 1.2%
Enrolment in a new prospective study 13 2.1% 1.2%
Pregnancy 12 1.9% 1.1%
Other 35 5.7% 3.2%
Non-discontinued 176 (6 deaths) N/A 176 100% 16.1%
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assumption on the data set with the full set of covariates
yielded global p-values of 0.3 and 0.8, using the anti-HIV
antiretroviral therapy encoding (ii) and (iv), respectively.
The proportional hazard hypothesis could not be rejected
as well with the other therapy encodings. This allowed
the subsequent fit of a main-effect multivariable Cox re-
gression model.
Table 4 reports the relative hazards of the main-effects
Cox models using the two different anti-HIV antiretro-
viral therapy encoding (ii) and (iv). These encodings
were the only ones showing significantly different
(defined with a p-value<0.05) hazards among such anti-
HIV treatment categories, therefore encodings (i) and
(iii) did not reveal differences among treatment strata.
Factors associated with an increased hazard of discontinu-
ation for adverse events were: an older age, a CDC stage C
vs. A, female gender, homo/bisexual risk group as com-
pared to the heterosexual category, HBsAg positivity, zi-
dovudine, stavudine, zalcitabine, didanosine, efavirenz, full
dose ritonavir, or indinavir intake, any NRTI+PI/r in-
take (excluding KaletraW and ReyatazW) as compared to
TruvadaW + SustivaW. The relative hazard (RH) of
AtriplaW compared to the TruvadaW + SustivaW category
was 0.99, 95% CI 0.12-8.44, p=0.99. By changing the refer-
ence categories, we found that any NRTI+PI/r combi-
nation (excluding KaletraW and ReyatazW) showed an
increased risk of adverse events as compared to any other
NRTI+NNRTI intake (not including TruvadaW, SustivaW,
or AtriplaW), with a RH of 2.49, 95% CI 1.22-5.06,
p=0.012. In addition, any NRTI+PI/r combination vs.
KaletraW and ReyatazW yielded a RH of 3.10, 95% CI 1.57-
6.09, p= 0.001.
Also, in order to analyze the possible role of the intro-
duction in Italy of tenofovir (November 2002), TruvadaW
(September 2005), and AtriplaW (October 2008), the cal-
endar year was stratified into: 1988–1996, 1997–1998,
1999–2002, 2003–2005, 2006–2008, and 2009–2010.
However, this did not lead to any appreciable difference
across time periods.
Of note, a trend toward an increased risk of adverse
events was observed for HIV genotype F1 (when
Table 2 Baseline chemical markers (with cut-offs) of the
study population (n=1,096)
Factor Strata n %
Bilirubin Normal 624 56.9%
High (>1.2 mg/dL) 31 2.8%
Unknown 441 40.2%
Total Cholesterol Normal 478 43.6%
High (≥200 mg/dL) 107 9.8%
Unknown 511 46.6%
Hemoglobin Low (<12 g/dL) 158 14.4%
Normal 593 54.1%
Unknown 345 31.5%
GammaGT Normal 453 41.3%
High (>60 IU/L) 145 13.2%
Unknown 498 45.4%
Glucose Normal 674 61.5%
High (>110 mg/dl) 34 3.1%
Diabetes (>126 mg/dL) 22 2.0%
Unknown 366 33.4%
GPT Normal 561 51.2%
High (>40 IU/L) 224 20.4%
Unknown 311 28.4%
HDL Low (<40 mg/dL) 217 19.8%
Normal 121 11.0%
Unknown 758 69.2%
LDL Normal 306 27.9%
High (≥130 mg/dL) 12 1.1%
Unknown 778 71.0%
Tryglicerides Normal 383 34.9%
high (≥150 mg/dL) 178 16.2%
Unknown 535 48.8%
MDRD Low (<60 mg/dL/1.73m2) 20 1.8%
Normal 694 63.3%
Unknown 382 34.9%
Figure 1 Flow chart of patients included in the study from the
whole CUSH HIV data base.
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Table 3 Characteristics of the study population (n=1,096)
Factor/strata n %
Female gender 372 33.9%
Non Italian nationality 284 25.9%




CDC stage A 495 45.2%
B 229 20.9%
C 372 33.9%






First-line anti-HIV therapy (encoding i) 2NRTI+1NNRTI 227 20.7%
2NRTI+1PI 214 19.5%
2NRTI+1PI/r 426 38.9%
Other combination 229 20.9%
First-line anti-HIV therapy (encoding iv) TruvadaW + SustivaW 47 4.3%
AtriplaW 14 1.2%
ReyatazW ± ritonavir + backbone 22 2.0%
KaletraW + backbone 389 35.5%
Any other NRTI+NNRTI 165 15.0%
Any other NRTI+PI 221 20.2%
Any other NRTI+PI/r 18 1.6%
Other combinations 220 20.1%
Non-anti-HIV therapies (concomitant) anti-TB 140 12.8%
anti-PCP 425 38.8%
anti-HCV 14 1.3%
other antibiotics 194 17.7%
other drugs 238 21.7%
HBsAg negative 978 89.2%
positive 56 5.1%
unknown 62 5.7%
HCVAb negative 771 70.3%
positive 247 22.5%
unknown 78 7.1%
Discontinuation/switch for adverse events 302 27.5%
Discontinuation/switch for other causes 618 56.4%
Non-discontinued first-line anti-HIV therapies 176 16.1%
Years 1988-1993 1994-1998 1999-2004 2005-2010
Discontinuation/switch for adverse events 17 92 108 85
Patients starting a first-line ART 88 229 349 430
PYFU 282.06 350.26 724.36 504.58
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compared to genotype B). Moreover, unknown TGL
showed a higher RH as compared to the corresponding
“normal” (<150 mg/dL) category. We also formally
tested for interactions between the calendar year and
the efavirenz intake, using an ANOVA comparison on
the nested models (i.e. with/without interaction), but the
more complex model did not show a higher likelihood
(p=0.5); the interaction term was not significant and the
significant effect of efavirenz was canceled out.
In order to better assess the role of CD4+ T cell
counts, different Cox regression models were fit with ei-
ther the sole CD4+ or log(CD4+) cell/mm3 count or in-
cluding the full covariate set with the exception of the
CDC stage. Only for the univariable log(CD4+) regres-
sion there was a significant (p<0.05) decreased hazard of
an adverse event per log(CD4+) higher (RH=0.88, 95%
CI 0.79-0.99).
As a sensitivity analysis, we repeated the multivariable
Cox regression using the subset of therapies posterior to
1998 (n=779, number of events=193, PYFU=1228.948,
incidence of 0.16 with a 95% CI of 0.14-0.18), including
only cART regimens (although 12/779, i.e. 1.5%, where
not 2NRTI+1NNRTI or 2NRTI+1PI±r regimens). The
described relative hazards did not change, and in
addition there was a significant reduced hazard of an ad-
verse event for any other/unknown risk group as com-
pared to the heterosexual category (RH=0.62, 95% CI
0.40-0.95, p=0.03), and a trend of increased hazard for
nevirapine (RH=4.42, 95% CI 0.92-21.12, p=0.06), fosam-
prenavir (RH=5.64, 95% CI 0.94-34.01, p=0.06), and nel-
finavir (RH=4.42, 95% CI 0.97-20.22, p=0.05). Moreover,
in this model a significant higher risk of discontinuation
for adverse events was demonstrated for HIV genotype
F1 (RH 2.63, 95% CI 1.22-5.67, p=0.013 when compared
to genotype B), while a trend was observed for genotype
C (RH 2.24, 95% CI 0.94-5.33, p=0.067).
Discussion and conclusion
Since adverse events are the most frequent reason for
first-line antiretroviral therapy discontinuation or switch,
investigation of variables associated with their occur-
rence in a routine clinical practice setting is of increas-
ing interest. Such an understanding is crucial to tailor
antiretroviral regimens on patients’ characteristics in
order to increase the probability of cART tolerability.
In this study several demographic, clinical, laboratory
and cART-related variables were investigated, providing
useful information for the management of antiretroviral
therapy. The prescribed antiretroviral drugs are main
determinants of treatment discontinuation for toxicity.
As expected, the use of older drugs such as zidovudine,
stavudine, zalcitabine, didanosine and full-dose ritonavir
was associated with increased risk of adverse events.
However, these drugs are no longer recommended for
first-line therapy because of their greater potential for
toxicity [17]. When considering individual drugs cur-
rently recommended as preferred or alternative options
in first-line regimens, an higher probability of treatment
discontinuation for adverse events was observed for efa-
virenz (RH 2.4, 95% CI 1.2-5.1, p=0.02). Despite efavi-
renz has demonstrated high virologic efficacy, both
neuropsychiatric and neurocognitive toxicity associated
with this drug are not negligible [5,18]. In a recent study,
it was shown that nearly 20% of patients discontinue efa-
virenz due to central nervous system adverse events
[19]. Since similar rates of virological response have
been observed for other recommended regimens, this
observation should be taken into account at the time of
prescription of fist-line cART and close clinical monito-
ring should be warranted in efavirenz-treated patients.
However, our analysis includes mainly patients treated
with non-co-formulated efavirenz, since the single tablet
regimen including efavirenz/tenofovir/emtricitabine is
available in Italy from October 2008, and its availability
seems to improve treatment convenience and related
quality of life [20].
In this study, female patients showed a higher risk of
treatment discontinuation for drug-related side effects,
in accordance with previous results [3,21] . This might
be due to peculiar gender-related pharmacokinetic char-
acteristics which could influence drug exposure [21,22].
An interesting finding is the increased risk of discon-
tinuation for adverse events observed in men who have
sex with men. This could be ascribed to a different per-
ception of side effects eventually related to sociocultural
barriers, as described among vulnerable populations [23].
Table 3 Characteristics of the study population (n=1,096) (Continued)
Numerical markers Median IQR
Calendar year 2003 1998-2006
Days on first-line anti-HIV therapy 379 131-855
Age (years) 36 31-43
Years from the first HIV positive test 0.5 0.1-3.4
HIV-RNA Log10 copies/mL 4.8 4.7-5.2
CD4+ T cells/mm3 194 122-233
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Unlike previous studies [2,3], in our population we did
not observe a strong relation between discontinuation
for toxicity and baseline CD4+ cells count or viral load.
Patients harboring HIV genotype F1 demonstrated an
higher risk of treatment discontinuation for adverse
events and a trend toward an association was observed
for genotype C. F1 subtypes have been mostly detected
in Latin America [24], where they were reported to be
associated with faster HIV progression [25], and Central
Africa [26]. F1-carrying patients in our sample were ge-
nerally immigrants from poor resources countries often
with non-steady residence in Italy. This may explain the
higher, though non-significant, frequency of interrup-
tions related to F1 subtypes (vs. B).
In agreement with previous studies [3], we confirmed
the increased predisposition of older patients to discon-
tinue antiretroviral therapy for side effects. This could be
related to several factors, as an altered drug pharmacoki-
netic (e.g. modification of absorption, protein binding or
distribution, impaired drug metabolism) and a potential
for drug interactions with co-medications. Since our data-
base does not include detailed data on co-medications
other than drugs used for the treatment of opportunistic
infections and co-infections, the potential role of drug-
drug interactions as a major determinant of treatment
discontinuation could not be assessed adequately.
Previous studies suggested that prescription of concomi-
tant medications used for the treatment of opportunistic
Figure 2 Kaplan-Meier estimations of the probability (with 95% confidence intervals) to be free of adverse events after initiating a
first-line antiretroviral therapy.
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infections could increase the risk of discontinuation
owing to cumulative toxicities or drug interactions [3]. In
our population we did not observe an increased risk of
discontinuation for adverse events in patients treated for
PCP, TB or HCV co-infection. However, patients with
Table 4 Multivariable Cox model fit: relative hazards of
adverse events, with two different antiretroviral therapy
encodings (n=1,096)
Factor RH 95% CI p-value
Lower Upper
calendar year (per more recent) 1.01 0.96 1.07 0.6462
gender M vs. F 0.52 0.38 0.71 <0.0001
age per one year older 1.04 1.02 1.05 <0.0001
nationality non-Italian vs. Italian 0.82 0.57 1.17 0.2724
nationality unknown vs. Italian 1.08 0.62 1.87 0.7941
risk homo/bisexual vs. heterosexual 2.03 1.40 2.94 0.0002
risk IDU vs heterosexual 1.16 0.75 1.79 0.5153
risk other/unknown vs. heterosexual 0.74 0.52 1.07 0.1090
years from first positive test 0.99 0.96 1.02 0.3804
CDC stage B vs. A 1.10 0.79 1.54 0.5716
CDC stage C vs. A 1.57 1.14 2.15 0.0051
HBsAg positive vs. negative 1.67 1.04 2.69 0.0356
HBsAg unknown vs. negative 1.11 0.54 2.28 0.7780
HCVAb positive vs. negative 1.02 0.69 1.52 0.9109
HCVAb unknown vs. negative 0.68 0.34 1.36 0.2766
CD4+ per cell/mm3 higher 1.00 1.00 1.00 0.8679
HIV-RNA per Log10 higher 0.85 0.68 1.07 0.1761
subtype 17 BF vs. B 1.49 0.81 2.75 0.1973
subtype 28 BF vs. B 0.96 0.56 1.65 0.8714
subtype 29 BF vs. B 0.90 0.38 2.15 0.8113
subtype C vs. B 1.87 0.83 4.18 0.1289
subtype F1 vs. B 1.89 0.94 3.83 0.0747
subtype other vs. B 1.46 0.75 2.86 0.2691
subtype unknown vs. B 0.95 0.70 1.29 0.7441
bilirubin high vs. normal 1.02 0.46 2.26 0.9576
bilirubin unknown vs. normal 0.67 0.42 1.06 0.0845
hemoglobin normal vs. low 0.97 0.66 1.40 0.8525
hemoglobin unknown vs. low 0.91 0.47 1.78 0.7903
gammaGT high vs. normal 0.93 0.62 1.39 0.7125
gammaGT unknown vs. normal 1.12 0.77 1.64 0.5507
glucose diabetes vs. normal 1.55 0.80 3.01 0.1959
glucose high vs. normal 1.73 0.92 3.26 0.0888
glucose unknown vs. normal 1.04 0.55 1.96 0.9142
GPT high vs. normal 1.20 0.87 1.66 0.2757
GPT unknown vs. normal 0.70 0.37 1.32 0.2691
HDL normal vs. low 1.04 0.60 1.81 0.8911
HDL unknown vs. low 0.97 0.35 2.67 0.9476
LDL high vs. normal 1.51 0.56 4.03 0.4137
LDL unknown vs. normal 1.62 0.58 4.51 0.3551
TGL high vs. normal 0.95 0.63 1.42 0.8048
TGL unknown vs. normal 1.65 1.11 2.44 0.0125
MDRD normal vs. low 1.41 0.58 3.41 0.4430
MDRD unknown vs. low 1.94 0.69 5.45 0.2098
Table 4 Multivariable Cox model fit: relative hazards of
adverse events, with two different antiretroviral therapy
encodings (n=1,096) (Continued)
anti-HCV therapy 0.73 0.22 2.41 0.6107
anti-TB therapy 0.93 0.63 1.37 0.7013
anti-PCP therapy 0.93 0.68 1.27 0.6533
other antibiotic therapy 0.99 0.71 1.37 0.9389
other concomitant drugs 0.76 0.56 1.03 0.0785
AtriplaW vs. TruvadaW+SustivaW 0.99 0.12 8.44 0.9901
ReyatazW vs. TruvadaW+SustivaW 0.27 0.03 2.27 0.2270
KaletraW vs. TruvadaW+SustivaW 1.26 0.53 2.96 0.6025
any other therapy vs.
TruvadaW+SustivaW
1.11 0.39 3.20 0.8408
any other NRTI+NNRTI vs.
TruvadaW+SustivaW
1.56 0.64 3.83 0.3267
any other NRTI+PI vs.
TruvadaW+SustivaW
1.59 0.62 4.04 0.3339
any other NRTI+PI/r vs.
TruvadaW+SustivaW
3.89 1.38 10.95 0.0101
Emtricitabine* (in the cART, yes vs. no) 1.19 0.46 3.07 0.7127
Lamivudine* (in the cART, yes vs. no) 1.21 0.70 2.09 0.5004
Abacavir* (in the cART, yes vs. no) 2.33 0.93 5.87 0.0719
Zidovudine* (in the cART, yes vs. no) 3.51 1.34 9.18 0.0107
Stavudine* (in the cART, yes vs. no) 2.84 1.06 7.60 0.0375
Zalcitabine* (in the cART, yes vs. no) 3.47 1.29 9.34 0.0136
Didanosine* (in the cART, yes vs. no) 2.27 1.29 3.98 0.0042
Tenofovir* (in the cART, yes vs. no) 2.00 0.65 6.20 0.2282
Nevirapine* (in the cART, yes vs. no) 1.42 0.67 2.98 0.3586
Efavirenz* (in the cART, yes vs. no) 2.40 1.14 5.03 0.0205
Atazanavir* (in the cART, yes vs. no) 0.15 0.02 1.34 0.0898
Fosamprenavir* (in the cART, yes vs. no) 2.77 0.76 10.09 0.123
Indinavir* (in the cART, yes vs. no) 1.76 1.04 3.00 0.0357
Lopinavir* (in the cART, yes vs. no) 0.55 0.23 1.33 0.1843
Nelfinavir* (in the cART, yes vs. no) 1.37 0.66 2.86 0.396
Ritonavit full dose* (in the cART,
yes vs. no)
2.76 1.39 5.52 0.0039
Saquinavir* (in the cART, yes vs. no) 1.75 0.91 3.36 0.0922
Ritonavir boosting dose* (in the cART,
yes vs. no)
1.19 0.41 3.44 0.7527
*Substituting anti-HIV therapy encoding (iv) to (ii) and fitting with the other
covariates (single drugs’ RH are mutually adjusted). Note that both encoding
(i) that compared 2NRTI+1NNRTI, 2NRTI+1PI, 2NRTI+1PI/r, others, and
encoding (iii) that compared therapy combinations with a frequency of at
least 10, did not show significantly different hazards (at p=0.05 level).
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AIDS-defining events were more likely to interrupt or
switch cART for drug-related side effects.
Co-infection with HBV or HCV have been claimed as
a predisposing factor for treatment discontinuation due
to hepatic adverse events [9]; however, this association
remain controversial [2,3]. In our population we did not
observe a significant role of HCV co-infection, but
HBsAg-positive patients showed an increased hazard of
adverse events. The importance of co-infection with
hepatitis viruses could be strictly related to the fre-
quency of prescription of specific antiretroviral drugs,
with older drugs bearing a higher risk of hepatotoxicity.
The calendar year was not showing an impact on the
hazard of toxicity/allergy events. A similar observation
has been previously described in other cohorts [2,27].
This could seem paradoxical since in recent years several
drugs with better tolerability profile have been intro-
duced in routine clinical practice. A possible explanation
of this finding can rely on the increased number of alter-
native regimens that have become available in recent
years; for this reason clinicians can be more prone to
switch drugs also for less severe adverse events. Unfortu-
nately, we could not verify this hypothesis since grading
of clinical adverse events was not available in our
database.
The potential association of treatment discontinuation
for side effects and baseline chemical parameters has
not been investigated in previous studies. Chemistry
characteristic can represent important tools on the basis
of which clinicians can choose the appropriate antiretro-
viral regimens in order to limit the occurrence of toxici-
ties. In our population, we did not observe any
association with the explored parameters; however, the
relevant proportion of missing data could have influ-
enced such finding masking the real effects in terms of
increased/reduced hazard of adverse events occurrence.
Moreover, only baseline markers were analyzed, while
the effect of current markers may be crucial, for instance
the raise levels of bilirubin during atazanavir-containing
antiretroviral therapy [28]. We decided not to perform
a time-dependent analysis given the high rate of mis-
sing information in the baseline variables. A few
multi-centric HIV study cohorts in Italy, specifically
the MASTER (www.mastercohort.it) and Icona (http://
www.fondazioneicona.org) foundations, and in Europe,
including the Copenhagen HIV Programme and Euro-
SIDA (http://www.cphiv.dk) record such detailed infor-
mation for all patients, besides the standard HIV
serologic markers [15,16].
Some limitations should be recognized when interpre-
ting the results of our study. First, cART toxicity was
analyzed considering only treatment modification, but
clinical events or alterations in laboratory parameters
not leading to treatment discontinuation were not
investigated, thus leading to an underestimation of over-
all drug-related side effects. There might be a population
bias, since the first-line anti-HIV therapies could have
been tuned appositely on the patients’ background, ba-
sing on the guidelines available at that time. This can be
truer for drug combinations circulating for a longer
time, whose adverse effect have been deeply disclosed.
Since this study is retrospective, the bias cannot be ruled
out even using strong selection criteria and a patient co-
hort with a high level of detail and follow up.
Another possible limitation of this study is that we
conducted a cause-specific analysis, ignoring the poten-
tial effects of competing events in the survival analysis;
such events may drive the happening of adverse effects,
and surely a design of a competing-risk analysis after
this study is warranted.
Given the current, fair, rate of virologic and immuno-
logic successes of first-line anti-HIV antiretroviral the-
rapies in the European Union and other developed
countries [29-32], along with the decrease of drug-
resistance prevalence [33-39], the objective is now the
prolongation of the therapy duration with the
minimization of adverse events. Intolerance/toxicity still
remains the major cause of drug discontinuation in Italy
[40]. Therefore, an effort in gathering data from all avail-
able sources to assess more precisely prognostic factors
and relative hazards of adverse events is warranted.
Eventually, a personalized scoring system might be in-
ferred, as it has been done with the prediction of virolo-
gic responses and time to virologic failure [41-44].
In conclusion, several predictors of treatment discon-
tinuation for drug-related adverse events were investi-
gated. These findings could help clinicians to identify
individuals at higher risk of developing toxicity, thus
allowing an improved prescription of antiretroviral regi-
mens tailored on patients’ characteristics. Moreover,
these results suggest the importance of anticipating the
probability of occurrence of adverse events in order to
ensure close clinical and laboratory monitoring and ad-
equate management of side effects which could improve
the durability of cART.
Additional file
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